Mohit Bhandari1, Winni Mathur2, Ravindra Kumar3, Arun Mishra2, Mahak Bhandari4. 1. Mohak Bariatrics and Robotics, Indore, India. drmohitbhandari@gmail.com. 2. Mohak Bariatrics and Robotics, Indore, India. 3. Central Research Laboratory, Sri Aurobindo Medical College and Post Graduate Institute, Indore, India. 4. Department of Surgery, Sri Aurobindo Medical College and Post Graduate Institute, Indore, India.
Abstract
BACKGROUND: Bariatric surgery, incretin-based therapy (glucagon-like peptide-1 analogues), and sodium-glucose co-transporter 2 (SGLT2) inhibitors have antidiabetic properties in morbidly obese patients. However, their comparative efficacy in treating type 2 diabetes mellitus (T2DM) in class I obese patients specifically in Indian has not been studied yet. This study evaluates and compares the efficacy and side effect of surgical and advanced medical management of T2DM in class I obese patients. METHODS: T2DM patients with body mass index ranging from 30 to 35 kg/m2 and with a median duration of 3 years and HbA1c level >7.5% were recruited for the study. Selection of treatment option that is bariatric surgery, GLP-1 analogues and SGLT2 inhibitor, was kept on patient's choice. Each group had 30 patients after 12 months of follow-up. Fasting plasma glucose (FPG), HbA1c, and lipid profile levels were assessed at baseline and after 12 months of follow-up. RESULTS: There was statistically significant lowering of HbA1c and FPG after 12 months in all the three groups. However, this lowering was clinically insignificant in GLP-1 and SGLT2 groups. There was also improvement in lipid profile values in all the three groups with significantly higher percentage change in bariatric surgery group when compared to other modalities. CONCLUSIONS: Bariatric surgery is a safe and effective procedure to treat T2DM in class I obese patients. It is also superior to advance medical treatment modalities such as GLP-1 analogues and SGLT2 inhibitors.
BACKGROUND: Bariatric surgery, incretin-based therapy (glucagon-like peptide-1 analogues), and sodium-glucose co-transporter 2 (SGLT2) inhibitors have antidiabetic properties in morbidly obesepatients. However, their comparative efficacy in treating type 2 diabetes mellitus (T2DM) in class I obesepatients specifically in Indian has not been studied yet. This study evaluates and compares the efficacy and side effect of surgical and advanced medical management of T2DM in class I obesepatients. METHODS: T2DM patients with body mass index ranging from 30 to 35 kg/m2 and with a median duration of 3 years and HbA1c level >7.5% were recruited for the study. Selection of treatment option that is bariatric surgery, GLP-1 analogues and SGLT2 inhibitor, was kept on patient's choice. Each group had 30 patients after 12 months of follow-up. Fasting plasma glucose (FPG), HbA1c, and lipid profile levels were assessed at baseline and after 12 months of follow-up. RESULTS: There was statistically significant lowering of HbA1c and FPG after 12 months in all the three groups. However, this lowering was clinically insignificant in GLP-1 and SGLT2 groups. There was also improvement in lipid profile values in all the three groups with significantly higher percentage change in bariatric surgery group when compared to other modalities. CONCLUSIONS: Bariatric surgery is a safe and effective procedure to treat T2DM in class I obesepatients. It is also superior to advance medical treatment modalities such as GLP-1 analogues and SGLT2 inhibitors.
Entities:
Keywords:
Bariatric surgery; Class I obesity; GLP-1 analogues; SGLT2 inhibitor
Authors: David E Cummings; Joost Overduin; Michael H Shannon; Karen E Foster-Schubert Journal: Surg Obes Relat Dis Date: 2005 May-Jun Impact factor: 4.734
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: Anita P Courcoulas; Steven H Belle; Rebecca H Neiberg; Sheila K Pierson; Jessie K Eagleton; Melissa A Kalarchian; James P DeLany; Wei Lang; John M Jakicic Journal: JAMA Surg Date: 2015-10 Impact factor: 14.766
Authors: Geltrude Mingrone; Simona Panunzi; Andrea De Gaetano; Caterina Guidone; Amerigo Iaconelli; Giuseppe Nanni; Marco Castagneto; Stefan Bornstein; Francesco Rubino Journal: Lancet Date: 2015-09-05 Impact factor: 79.321
Authors: Daniel J Drucker; Steven I Sherman; Fred S Gorelick; Richard M Bergenstal; Robert S Sherwin; John B Buse Journal: Diabetes Care Date: 2010-02 Impact factor: 19.112
Authors: Claudia A Velez-Viveros; José G González-González; Marcela Rodríguez-Flores; Leonardo G Mancillas-Adame Journal: Obes Surg Date: 2018-03 Impact factor: 4.129